N. Leigh Anderson

N. Leigh Anderson, Ph.D. is a Founder and CEO of SISCAPA Assay Technologies, (www.SISCAPA.com). His interests are focused on the proteins of human blood as disease biomarkers, and the introduction of biomarker panels in clinical diagnostics using peptide-level mass spectrometry assays (the SISCAPA technology). Dr. Anderson obtained a BA in Physics from Yale and a Ph.D. in Molecular Biology from Cambridge University, working at the MRC laboratory of Molecular Biology on hemoglobin structure with M. F. Perutz, and later with Sydney Brenner. Subsequently he co-founded (with Dr. Norman Anderson) the Molecular Anatomy Program at the Argonne National Laboratory (Chicago) where his work in the development of 2-D electrophoresis technology earned him the 1983 Pittsburgh Conference Analytical Chemistry Award and the American Association for Clinical Chemistry’s Young Investigator Award. After leaving Argonne, Dr. Anderson was a founder and Chief Scientific Officer at Large Scale Biology Corporation, where he co-led a highly successful Nasdaq IPO in 2000. Beginning work in clinical mass spectrometry in 2002, he founded and is CEO of the Plasma Proteome Institute, a non-profit biomedical scientific research institute in Washington, D.C., and SISCAPA Assay Technologies, Inc., whose core technology he invented and developed. He has served on the boards of directors of three public technology companies including Dade Behring, a global diagnostics company acquired by Siemens, Luna Innovations and Large Scale Biology. He has published 175 papers, been granted 44 US Patents, and was awarded the 2009 Human Proteome Organization (HUPO) Distinguished Achievement Award in Proteomic Science. SISCAPA received the 2014 HUPO Science and Technology Award.